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Nicolas H. Pope, MD*, and Gorav Ailawadi, MD*,†Introduction
Mitral regurgitation (MR) represents the most prevalentacquired valvular pathology, estimated to affect more
than 3.5 million Americans.1 For a select group of high-risk
patients, surgical repair of signiﬁcant MR is not feasible
because of substantial medical comorbidities. Though
seldom used by mitral surgeons, an edge-to-edge technique
(Alﬁeri repair) has been shown to be effective at decreasing
MR without signiﬁcant risk of mitral stenosis.2 The
MitraClip (Abbot Vascular, Menlo Park, CA) is a catheter-
based device, based on the Alﬁeri technique, which brings
together the anterior and posterior mitral leaﬂets at the point
of maximal regurgitation to improve coaptation and
reduce MR.
MitraClip is currently approved for high–surgical risk
patients with degenerative MR (DMR) and ideally a ﬂail gap
o10 mm and a ﬂail width o15 mm.3-5 Patients with
functional MR (FMR) can be currently treated in the
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Important exclusions for MitraClip therapy include the
following: (1) a resting effective oriﬁce area o4 cm2, as
coaptation results in a slight but potentially signiﬁcant
reduction in valve area,3,5 (2) multiple regurgitant jets
particularly at the commissures, (3) calciﬁed leaﬂet edges at
the site of regurgitation (mitral annular calciﬁcation is not an
exclusion), and (4) mitral regurgitation due to rheumatic fever
or endocarditis. Additionally, caution should be exercised in
using the MitraClip device in patients with end-stage renal
disease, as late calciﬁcation and resultant mitral stenosis have
been reported in this patient population.8
The procedure is performed in a hybrid operating room or
catheterization laboratory under general anesthesia using
both transesophageal echocardiographic guidance and
ﬂuoroscopic guidance. The device is placed via percutaneous
24-F femoral venous system across the atrial septum. The
use of 3-dimensional echocardiography is extremely helpful
in positioning the device for optimal results. Although the
goal is minimal residual MR, procedural success is reduction
in MR to 1þ to 2þ. If sufﬁcient reduction in MR is not seen
following initial clip placement, a second device is often
placed as long as there is sufﬁcient valve area.
We describe the technique for transcatheter mitral valve
repair using the MitraClip device for both FMR and DMR.Procedure
Refer to Figures 1-12 for the detailed procedure.219
Figure 1 (A) MitraClip percutaneous mitral valve repair system. The system comprises (1) a steerable guide catheter (large arrow), which
allows for delivery of MitraClip across the atrial septum, (2) the Clip Delivery System (CDS, arrowhead) that is highly maneuverable to allow
for proper MitraClip device positioning, and (3) the MitraClip device itself (arrowhead).
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Figure 1 (Continued) (B) The MitraClip grasps the mitral leaﬂet between cobalt chromium grasper arms (arrowheads) and gripper arms
(arrows). The polyester cover helps to promote tissue ingrowth and scar formation between the anterior and posterior leaﬂets. (Courtesy of
Abbot Vascular. 2014, All Rights Reserved.) (Color version of ﬁgure is available online at www.optechtcs.com.)
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Figure 2 Caricature of transeptal access in ideal position for MitraClip insertion. Percutaneous access to the right femoral vein is achieved.
Under ﬂuoroscopic and echocardiographic guidance, the fossa ovalis is crossed and a guidewire is advanced into the left atrium. The ideal
transeptal location is posterior (away from the aortic valve) with a height above the plane of mitral valve coaptation of 3.5-4 cm. A dilator is
then advanced over the guidewire and the patient is heparinized with an ACT goal of 250 seconds. The 24-F steerable guide is placed from the
femoral vein across the septum into the left atrium. ACT ¼ activated clotting time.
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Figure 3 X-plane TEE demonstrating positioning for transeptal puncture. Ideal transeptal location is critical and performed under TEE
guidance. Here, TEE demonstrates ideal position of transeptal puncture (deformation of the atrial septum) in the short access and bicaval
views. The optimal height from the mitral valve plane at which the transeptal puncture should be made is 3.5-4 cm.3 This distance is
determined using both a short-axis and 4-chamber view on TEE. In DMR, the plane of leaﬂet coaptation tends to be close to the level of the
mitral annulus.3 In FMR, the plane of leaﬂet coaptation tends to lie below the mitral annulus, typically because of tethering. Thus, the
pathology will help determine where the transeptal puncture should be performed. TEE ¼ transesophageal echocardiography.
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Figure 4 A TEE demonstrating 24-F steerable guide across septum. Following transeptal puncture, a 0.035-in. Super Stiff guidewire with a
7-cm ﬂoppy tip is passed through the transeptal catheter and into the left atrium. Height measurements are taken again to ensure ideal
location of the transeptal puncture. Once conﬁrmed, systemic heparin is administered for an ACT goal 4250 seconds. The 24-F guide
catheter is advanced over the wire into the left atrium under echo guidance. ACT ¼ activated clotting time; TEE ¼ transesophageal
echocardiography.
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Figure 5 Fluoroscopic view of MitraClip device in left atrium. The CDS with a clip in place is then passed through the sheath under
ﬂuoroscopic guidance. Both the delivery sheath and the CDS are equipped with radiopaque markings (arrows). CDS ¼ Clip Delivery System.
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Figure 6 A 3D TEE of Open MitraClip in left atrium. 3D-echocardiography is helpful to position the MitraClip over the pathology and to
correctly orient the device (open to 1801) perpendicular to the valve leaﬂets. 3D ¼ 3-dimensional; TEE ¼ transesophageal echocardiography.
(Color version of ﬁgure is available online at www.optechtcs.com.)
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Figure 7 TEE demonstrating the MitraClip device across mitral valve. The MitraClip is advanced under TEE guidance across the mitral valve
into the left ventricle below the plane of coaptation and the clip is closed to 1201 in preparation for leaﬂet capture. TEE ¼ transesophageal
echocardiography.
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Figure 8 TEE of MitraClip device closed. Capture of the mitral leaﬂets is then accomplished by slow withdrawal of the CDS (MitraClip) with
the clip opened to 1201 and closing the grippers (A). The MitraClip is partially closed and adequate anterior and posterior leaﬂet insertion is
conﬁrmed in multiple 2D TEE views including 2-chamber, 4-chamber, and intercommisural views before assessment of MR reduction. Once
adequate leaﬂet insertion is ensured, the MitraClip is closed fully using x-plane, and MR reduction is assessed. (B) The mitral valve oriﬁce
from the left atrium (the traditional surgeon's view) demonstrates a double-lumen valve oriﬁce after clip placement. If the position or purchase
is not ideal or adequate, the graspers can be released and the clip repositioned before deployment. 2D ¼ 2-dimensional; CDS ¼ Clip Delivery
System; TEE ¼ transesophageal echocardiography.
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Figure 8 (Continued) (C) TEE image of leaﬂet capture by grasper arms (arrow). TEE ¼ transesophageal echocardiography.
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Figure 9 A 3D TEE with MitraClip deployed. 3D-echocardiography demonstrates adequate leaﬂet tissue capture, clip position and a double
oriﬁce mitral valve. Transvalvular gradients are measured directly to detect hemodynamically signiﬁcant mitral stenosis prior to release of clip.
3D ¼ 3-dimensional; TEE ¼ transesophageal echocardiography. (Color version of ﬁgure is available online at www.optechtcs.com.)
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Figure 10 Placement of a second MitraClip. Following clip placement, transvalvular gradients are again measured and effective valve oriﬁce
area is evaluated by TEE. If moderate MR is still present, a second clip may be positioned in the same fashion under TEE (A) and ﬂuoroscopic
(B) guidance. The second clip is placed either medial or lateral to the ﬁrst clip over the area of greatest regurgitation. Once the clip orientation
is conﬁrmed (perpendicular to the valve coaptation line), the clip is closed to cross the mitral valve. Fluoroscopic guidance is used to ensure
the second clip (arrowhead) is not interacting with the ﬁrst clip (B, arrow). TEE ¼ transesophageal echocardiography. (Color version of ﬁgure
is available online at www.optechtcs.com.)
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Figure 10 (Continued)
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Figure 11 A TEE of MitraClip to treat degenerative MR. Predevice (A) and postdevice (B) TEE evaluation conﬁrms signiﬁcant reduction in MR
in an inoperable patient with DMR due to a porcelain aorta. TEE ¼ transesophageal echocardiography. (Color version of ﬁgure is available
online at www.optechtcs.com.)
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Figure 11 (Continued)
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Figure 12 A TEE of MitraClip to treat functional MR. Predevice (A) and postdevice (B) TEE images conﬁrm reduction of MR in a patient with
FMR in the REALISM trial. After conﬁrmed adequate reduction in MR, the guide catheter is then removed from the left atrium. Protamine is
then given until ACT normalizes and the femoral sheath is removed. A 2-0 silk purse-string suture is made in the soft tissue or skin and tied
down. Hemostasis is achieved with direct manual compression or rarely with a Perclose (Abbot Vascular, Menlo Park, CA) device. Antiplatelet
therapy with aspirin is instituted postprocedurally. Patients are generally observed for 1-2 days and discharged home. ACT ¼ activated
clotting time; REALISM ¼ Real World Expanded Multi-center Study of the MitraClip System; TEE ¼ transesophageal echocardiography.
(Color version of ﬁgure is available online at www.optechtcs.com.)
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Figure 12 (Continued)
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Minimally invasive and catheter-based therapies are chang-
ing the way many surgeons treat aortic valve disease. The
advent of technology such as MitraClip device allows us to
offer effective therapy to patients who would not be
considered for open mitral valve repair.
The safety and efﬁcacy of MitraClip was demonstrated in
the Endovascular Valve Edge-to-Edge Repair Study II trial
(EVEREST), which compared surgical mitral valve repair to
percutaneous edge-to-edge repair with MitraClip. At 12
months follow-up, 73% of patients in the surgical group had
a durable repair, compared with 55% in the percutaneous
group.4 Without question, surgical repair is more effective at
MR reduction. However, the MitraClip device is extremely
safe with very low rates of complications (15% percutaneous
vs 48% open repair).4 Importantly, patients in both arms
showed reduced left ventricular size and New York Heart
Association Heart functional classiﬁcation and improved
quality of life at 12 months.4
Patient selection is key to ensuring both initial technical
and long-term procedural success. The MitraClip is currently
approved by the Food and Drug Administration for
treatment of severe (Z3þ), symptomatic DMR in patients
considered to be too high risk for surgical intervention.9
As with many new techniques, there exists a steep
learning curve in transcatheter mitral valve repair. Although
initial attempts frequently take less experienced teams
longer, it is important to note that increased procedural
times likely do not contribute signiﬁcantly to increased
morbidity as with cross-clamp and cardiopulmonary bypass
times with open repair. Technical success is highly depend-
ent on adequate transesophageal echocardiographic win-
dows, and collaboration with a skilled and experienced
echocardiographer is necessary. Most patients remain
remarkably hemodynamically stable during this beating-
heart procedure and require minimal intraprocedural or
postprocedural hemodynamic support.Transcatheter mitral valve repair offers symptomatic
patients with moderate to severe MR and an unacceptable
operative risk, improved left ventricular mechanics, im-
proved functional status, and less periprocedural morbidity
and mortality in comparison with traditional open repair.
MitraClip placement should be considered for poor
operative candidates with severe MR and amenable anatomy.
The Cardiovascular Outcomes Assessment of the MitraClip
Percutaneous Therapy for Heart Failure Patients With
Functional Mitral Regurgitation trial will assess the outcome
in patients with FMR who often are not ideal candidates for
surgery. Surgeons should be integral members of the heart
team and should be involved in patient selection and
performance of the procedure.References
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